Supplementary Materials

Supplementary Material for:

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe

Evan Phillips, Oula Penate-Medina, Pat B. Zanzonico, Richard D. Carvajal, Pauliah Mohan, Yunpeng Ye, John Humm, Mithat Gönen, Hovanes Kalaigian, Heiko Schöder, H. William Strauss, Steven M. Larson, Ulrich Wiesner, Michelle S. Bradbury*

*Corresponding author. E-mail: bradburm{at}mskcc.org and ubw1{at}cornell.edu

Published 29 October 2014, Sci. Transl. Med. 6, 260ra149 (2014)
DOI: 10.1126/scitranslmed.3009524

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Whole-body PET-CT imaging biodistributions of 124I-cRGDY–PEG–C dots with time.
  • Fig. S2. RadioTLC chromatograms of plasma specimens and standards.
  • Fig. S3. RadioTLC chromatograms of urinary specimens and standards.
  • Table S1. Photophysical characterization of cRGDY–PEG–C dots by fluorescence correlation spectroscopy.
  • Table S2. Post-release product criteria for cRGDY–PEG–C dots.
  • Table S3. Stability measurements of cRGDY–PEG–C dot batches (n = 2) by fluorescence correlation spectroscopy.
  • Table S4. Individual patient PK results for intravenously injected 124I-cRGDY–PEG–C dots.
  • Table S5. Summary of PK results for 124I-cRGDY–PEG–C dots delivered by systemic injection.
  • Table S6. Percentage of total body activity of 124I-labeled nanoparticle or free iodide (124I).
  • Table S7. Organ- and tissue-specific cumulative 124I activities by patient.
  • Table S8. Complete metabolic profile in male subjects.
  • Table S9. Complete metabolic profile in female subjects.
  • Table S10. Analysis of urine specimens.
  • Table S11. Hematologic and nonhematologic adverse events.
  • References (4246)

[Download PDF]